Key Takeaways
- • ICG Enterprise Trust (ICGT) posted a 3.3% total investment return, or NAV total return, for the six months to 31 July 2026, on a £1.3bn private equity portfolio.
- • Direct investments returned 6.8% and primary fund investments grew 2.6%, offsetting a 3.2% decline in secondary stakes.
- • Portfolio companies grew revenue 11% and operating profit 16% over 12 months, with the top 30 holdings representing 37% of assets.
- • The trust made £84m of disposals and expects a further £70m from the exit of its largest holding, Exail (3.4%), in the second half.
- • ICGT returned £20m through buybacks and declared a second quarterly dividend of 9.5p, keeping it on track for a 42p full-year target, up 8% year on year.
Summary
By investment type, direct investments, where ICGT co-invests in private companies alongside a fund manager, returned 6.8%. Primary investments in private equity funds bought at launch grew 2.6%. These gains were partly offset by a 3.2% decline in secondary stakes, which are fund interests bought from other investors. Portfolio companies continued to grow, with revenue up 11% and operating profit up 16% over the past 12 months. The global portfolio is diversified, with its top 30 holdings accounting for 37% of assets. The trust's three best-performing holdings in the half were all US companies: Brooks Automation, a semiconductor support services provider; pest controller Greenix; and New York-based accountants CohnReznick.
Portfolio manager Oliver Gardey continued to recycle capital during the period, completing £84m of disposals. The largest was the £23m exit from Boston-based Curium Pharma. A further £70m of proceeds may be received in the second half from the exit of Exail, a French provider of autonomous systems for the aerospace and maritime sectors and the trust's largest holding at 3.4%. On new commitments, the trust made £65m of new investments and £104m of new fund commitments, including to its in-house manager Intermediate Capital Group (ICG) and external managers Gridiron, TJC and Archimed.
On shareholder returns, the trust, which yields around 3%, bought back £20m of shares and declared a second quarterly dividend of 9.5p per share. This forms part of a 42p target for the financial year, an 8% increase on the prior year.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.